MYD88-independent growth and survival effects of Sp1 transactivation in Waldenstrom macroglobulinemia

A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstrom macroglobulinemia

(2013) G. Yang et al.   BLOOD

MYD88 L265P mutation in Waldenstrom macroglobulinemia

(2013) S. Poulain et al.   BLOOD

MYD88 L265P in Waldenstrom macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction

(2013) L. Xu et al.   BLOOD

Tetra-O-methyl nordihydroguaiaretic acid, an inhibitor of Sp1-mediated survivin transcription, induces apoptosis and acts synergistically with chemo-radiotherapy in glioblastoma cells

(2013) Angel Mauricio Castro-Gamero et al.   INVESTIGATIONAL NEW DRUGS

Ibrutinib in chronic lymphocytic leukemia and B cell malignancies

(2013) Jennifer R. Brown   LEUKEMIA & LYMPHOMA

MYD88 L265P Somatic Mutation in Waldenström's Macroglobulinemia

(2012) Steven P. Treon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Significant Biological Role of Sp1 Transactivation in Multiple Myeloma

(2011) M. Fulciniti et al.   CLINICAL CANCER RESEARCH

Terameprocol (Tetra-O-Methyl Nordihydroguaiaretic Acid), an Inhibitor of Sp1-Mediated Survivin Transcription, Induces Radiosensitization in Non-small Cell Lung Carcinoma

(2010) Yunguang Sun et al.   Journal of Thoracic Oncology

Oncogenically active MYD88 mutations in human lymphoma

(2010) Vu N. Ngo et al.   NATURE

Bone marrow microenvironment and the identification of new targets for myeloma therapy

(2008) K Podar et al.   LEUKEMIA